Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation

Shinichiro Okamoto, Satoshi Takahashi, Masatoshi Wakui, Akaru Ishida, Ryuji Tanosaki, Yasuo Ikeda, Shigetaka Asano

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We treated 13 patients with morphologically advanced myelodysplastic syndrome using cytosine arabinoside and total body irradiation, followed by allogeneic marrow transplantation from HLA-identical sibling donors. Granulocyte colony-stimulating factor (G-CSF) was added to the preparative regimen to selectively increase chemosensitivity of leukaemic cells and to improve transplant outcome. No regimen-related deaths occurred, and no side- effects related to the addition of G-CSF were observed except for transient mild bone pain. At a median follow-up time of 39 months the projected 5-year disease-free survival and 5-year overall survival were 67.7% and 75.5%, respectively, with only one case showing cytogenetic relapse. The preparative regimen including G-CSF is feasible, and preliminary results seem to be encouraging. However, a larger trial is clearly warranted to evaluate its efficacy.

Original languageEnglish
Pages (from-to)569-573
Number of pages5
JournalBritish Journal of Haematology
Volume104
Issue number3
DOIs
Publication statusPublished - 1999 Jan 1

Keywords

  • Allogeneic bone marrow transplantation
  • Chemosensitization
  • Conditioning
  • G-CSF
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation'. Together they form a unique fingerprint.

  • Cite this